| Net Loss per Share |
11. Net Loss per Share
The following table sets
forth the computation of basic and diluted net loss per common share attributable to stockholders:
| Schedule of computation of basic and diluted net loss per
common share | |
| | | |
| | | |
| | | |
| | |
| | |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Numerator: | |
| | | |
| | | |
| | | |
| | |
| Net income (loss) attributable to common stockholders, basic | |
$ | (1,835 | ) | |
$ | 2,700 | | |
$ | (3,145 | ) | |
$ | 1,930 | |
| Series D preferred stock dividend | |
| (227 | ) | |
| – | | |
| (227 | ) | |
| – | |
| Effect of potentially dilutive securities: | |
| | | |
| | | |
| | | |
| | |
| After-tax interest expense on convertible notes | |
| – | | |
| 14 | | |
| – | | |
| 14 | |
| Net income (loss) attributable to common stockholders | |
$ | (2,062 | ) | |
$ | 2,714 | | |
$ | (3,372 | ) | |
$ | 1,944 | |
| Denominator: | |
| | | |
| | | |
| | | |
| | |
| Weighted-average common shares outstanding, basic | |
| 186,174,045 | | |
| 51,776,206 | | |
| 179,284,550 | | |
| 47,154,964 | |
| Effect of potentially dilutive securities: | |
| | | |
| | | |
| | | |
| | |
| Convertible notes | |
| – | | |
| 14,500,000 | | |
| – | | |
| 7,250,000 | |
| Restricted stock | |
| – | | |
| – | | |
| – | | |
| 3,513,362 | |
| Weighted-average common shares outstanding, diluted | |
| 186,174,045 | | |
| 66,276,206 | | |
| 179,284,550 | | |
| 57,918,326 | |
| | |
| | | |
| | | |
| | | |
| | |
| Net income (loss) per share attributable to common stockholders, | |
| | | |
| | | |
| | | |
| | |
| Basic | |
$ | (0.01 | ) | |
$ | 0.05 | | |
$ | (0.02 | ) | |
$ | 0.04 | |
| Diluted | |
$ | (0.01 | ) | |
$ | 0.04 | | |
$ | (0.02 | ) | |
$ | 0.03 | |
The Company excluded the
following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss
per share for the periods indicated, since their inclusion would be anti-dilutive:
| Schedule of anti-dilutive shares | |
| | | |
| | | |
| | | |
| | |
| | |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Series C Preferred Shares | |
| 11,983,000 | | |
| – | | |
| 11,983,000 | | |
| – | |
| Series D Preferred Shares | |
| 34,677,751 | | |
| – | | |
| 34,677,751 | | |
| – | |
| Senior Secured Notes, including accrued interest | |
| 168,184 | | |
| 140,612 | | |
| 168,184 | | |
| 140,612 | |
| Convertible Notes, excluding accrued interest | |
| 75,000,000 | | |
| – | | |
| 75,000,000 | | |
| – | |
| Warrants to purchase common stock | |
| 85,063,587 | | |
| 62,549,982 | | |
| 85,063,587 | | |
| 62,549,982 | |
| Stock options to purchase common stock | |
| 50,843,036 | | |
| 1,103,451 | | |
| 50,843,036 | | |
| 1,103,451 | |
| Unvested Shares | |
| 1,129,630 | | |
| 1,129,630 | | |
| 1,129,630 | | |
| 1,129,630 | |
| Restricted stock | |
| – | | |
| 65,000,000 | | |
| – | | |
| – | |
| Restricted stock units | |
| 25,000 | | |
| 25,000 | | |
| 25,000 | | |
| 25,000 | |
| Anti-dilutive shares | |
| 258,890,188 | | |
| 129,948,675 | | |
| 258,890,188 | | |
| 64,948,675 | |
|